According to a recent LinkedIn post from 9fin, the firm is closely tracking the evolving restructuring of specialty chemicals group Arxada, which could become a key European workout in 2026. The post outlines a timeline that includes a business reorganisation, advisor mandates by first-lien lenders and SUN holders, and formation of a SUN creditor co-op ahead of any formal proposal.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
The post further notes that an initial amend-and-extend deal between sponsors Bain and Cinven and senior secured lenders appeared to leave unsecured creditors sidelined, prompting rejection by first-lien lenders and a revised proposal. That updated deal reportedly features a €200 million sponsor injection, extended maturities to 2031, and differing sign-up rates between senior secured and SUN holders.
According to 9fin’s summary, Arxada’s amended documentation now incorporates a broad set of liability-management exercise blockers, including bespoke “Pfleiderer-style” protections that may constrain aggressive restructuring tactics. The remaining question highlighted is whether Arxada can secure 75% support for a U.K. Scheme or will need to rely on cross-class cramdown via a Restructuring Plan.
For investors in European credit and special situations, the development suggests that Arxada could be a bellwether for creditor dynamics and documentation terms in upcoming restructurings. The focus on LME blockers and potential use of U.K. restructuring tools may signal a tougher negotiating environment for sponsors and increased relevance of legal structuring in recovery outcomes.
The post also directs readers to 9fin’s legal analysis of the new LME blocker provisions, emphasizing the firm’s role as an information and analytics provider in this complex process. While the outcome for Arxada’s capital structure remains uncertain, the situation may offer insight into evolving market standards for sponsor support, creditor protections, and cross-class negotiations in European leveraged credit.